Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.57 |
| ▸ | KRAS | P01116 | 6/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | F11 | P03951 | 2/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | KLK1 | P06870 | 1/20 | 0.52 |
| ▸ | KLK2 | P20151 | 1/20 | 0.52 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.52 |
| ▸ | KLK13 | Q9UKR3 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27286988 | 0.98 | KLKB1 (0.58) | KLKB1KRASALBF11F10 | |
| SCHEMBL27287192 | 0.91 | KRAS (0.58) | KLKB1KRASCD274 | |
| SCHEMBL27286874 | 0.91 | KRAS (0.58) | KLKB1KRASCD274 | |
| SCHEMBL27288453 | 0.87 | KLKB1 (0.49) | KLKB1KRASALBF11F10 | |
| SCHEMBL27286891 | 0.78 | TEAD4 (0.48) | KLKB1KRASCD274 | |
| SCHEMBL18257587 | 0.78 | KLKB1 (0.65) | KLKB1KRASPLAUCD274 | |
| SCHEMBL26951832 | 0.76 | KRAS (0.55) | KLKB1KRASPLAUCD274 | |
| SCHEMBL23743618 | 0.75 | KLKB1 (0.59) | KLKB1KRASPLAUCD274 | |
| SCHEMBL22199698 | 0.75 | CD274 (0.63) | KLKB1CD274 | |
| SCHEMBL24218598 | 0.75 | KLKB1 (0.59) | KLKB1KRASPLAUCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | KLKB1 564/4885KRAS 2827/4885ALB 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.